Pediatric Respiratory Disease Therapeutics Market Size and Share
| Study Period | 2021 - 2030 |
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| CAGR | 5.60% |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Pediatric Respiratory Disease Therapeutics Market Analysis by Mordor Intelligence
The Pediatric Respiratory Disease Therapeutics Market is expected to register a CAGR of 5.6% during the forecast period.
The pandemic significantly impacted the pediatric respiratory disease therapeutics market as the demand for pediatric respiratory disease therapeutics products increased owing to the increased risk of respiratory illness. For instance, as per a study published by the NCBI in September 2022, low-field magnetic MRI showed persistent pulmonary dysfunction in both children and adolescents who recovered from COVID-19 and with long COVID. Similarly, per the study published by the IJP in November 2021, the pandemic has brought significant challenges to childcare worldwide. Respiratory disease therapeutics such as anti-inflammatory drugs, bronchodilators, and combination drugs are generally used for the treatment of various respiratory diseases. Thus, the increasing incidence of respiratory diseases among pediatrics and continuous treatment during the pandemic helped the market to maintain considerable growth. With the emergence of the new strain, the market is expected to move upward over the forecast period.
The increasing prevalence of chronic respiratory diseases and increasing research and development in drug discovery for respiratory diseases are the major drivers for the market. For instance, as per the report published by the WHO in October 2022, an estimated 10.6 million people suffered from tuberculosis (TB) in 2021 globally of which 1.2 million were children. The report also stated that TB is prevalent in all countries and age groups. In addition, the burden of asthma and allergic diseases continues to increase among pediatrics. Moreover, every year pediatric respiratory infections impose a significant burden on the global healthcare system in terms of manpower and resource utilization.
Furthermore, as per the October 2021 CDC report, there were more than 317 cases of tuberculosis disease among children aged 14 years or younger in the United States, accounting for 4.0% of all people reported with tuberculosis nationally in 2021. According to UNICEF data published in August 2022, there were more than 1,400 cases of pneumonia per 100,000 children, or 1 case in 71 children each year, globally, with the highest incidence occurring in South Asia (2,500 cases per 100,000 children) and West and Central Africa (1,620 cases per 100,000 children).
The increasing research and development in drug discovery is also another driving factor for the market. For instance, as per the journal published by the Frontiers Organization in October 2021, research is being conducted to identify prognostic respiratory disorder/disease progression-specific biomarkers that can predict disease course in children and to develop scoring and risk stratification systems. Similarly, in September 2021, Children's National Hospital received USD 2.13 million in awards from the National Institutes of Health's (NIH) National Heart, Lung and Blood Institute to accelerate research work and develop new diagnostic tools and innovative precision medicine related to treatments for kids with down syndrome experiencing respiratory viruses. It is expected that such advancements may create new opportunities for the market and may encourage new players to enter the market.
Global Pediatric Respiratory Disease Therapeutics Market Trends and Insights
The Asthma Segment is Expected to Witness Considerable Growth Over the Forecast Period
Asthma is the most common chronic respiratory disease affecting children globally. Asthma is a chronic (long-term) condition that affects the airways in the lungs. The airways of asthma patients can sometimes become inflamed and narrow. This makes it difficult for air to flow out of the airways when exhaling. Asthma is a major non-communicable disease (NCD) and can also affect adults.
The increasing number of pediatric asthma cases is one of the major drivers for the segment's growth. For instance, per the journal published by the ERJ open research in August 2022, a study based on the ISAAC questionnaire reported a prevalence rate of bronchial asthma of 13.1% in children aged 11 to 16 across the globe. Similarly, per the report published by the CDC in May 2022, 1 in 12, about 6.0 million children in the United States aged 0-17 years, suffer from asthma every year. Such instances indicate that the demand for asthma drugs and therapeutics is anticipated to increase, propelling segment growth.
The new product launch and approvals of drugs for treating asthma in children are also anticipated to propel the segment growth. For instance, in October 2021, the United States Food and Drug Administration (FDA) approved Dupixent (dupilumab) as an add-on maintenance treatment for patients aged 6 to 11 years with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid-dependent asthma. Similarly, in December 2021, AstraZeneca and Amgen's Tezspire (tezepelumab-ekko) has been approved in the United States for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
North America is Expected to Witness Significant Growth Over the Forecast Period
North America is expected to dominate the overall pediatric respiratory disease therapeutics market over the forecast period. The factors driving the market are increasing cases of pediatric respiratory diseases, increasing research work, and continuous product launches and approvals. According to a report published by Asthma Canada in June 2021, more than 850,000 children under the age of 14 have asthma, making it the most common chronic disease among children and the leading cause of both school absenteeism and hospitalization in Canada. Similarly, as per the journal published by the CMAJ Group in May 2021, asthma is the most common chronic disease in children, with a prevalence of 15.0% to 25.0% in Canada.
Key product launches, high concentration of market players or manufacturer's presence, acquisition and partnerships among major players, and increasing cases of respiratory diseases and research works and clinical trials in the United States are some of the factors driving the growth of the pediatric respiratory disease therapeutics market in the country. For instance, in April 2021, Sanofi's Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in the Phase 3 trial.
Competitive Landscape
The pediatric respiratory disease therapeutics market is moderately competitive due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold market shares and are well-known including Novartis AG, Bayer AG, GlaxoSmithKline plc, Merck & Co, Boehringer Ingelheim GmbH, AstraZeneca plc among others.
Pediatric Respiratory Disease Therapeutics Industry Leaders
-
Regeneron Pharmaceuticals
-
Boehringer Ingelheim International GmbH
-
GlaxoSmithKline plc
-
F. Hoffmann-La Roche AG
-
Novartis AG
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- In September 2022, AstraZeneca and Sanofi's Beyfortus (nirsevimab) was recommended for registration in the European Union (EU) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season.
- In June 2022, Glenmark Pharmaceuticals launched the novel fixed-dose combination (FDC) drug - Indacaterol plus Mometasone for patients suffering from uncontrolled asthma in India. The company has launched this fixed-dose combination (FDC) drug under the brand name Indamet.
Global Pediatric Respiratory Disease Therapeutics Market Report Scope
Pediatric respiratory disease therapeutics are specially approved medications to treat or alleviate respiratory diseases in pediatrics. Respiratory diseases are found to affect air passages, including nasal passages, bronchi, trachea, and lungs. Therefore they are also the major cause of mortality and morbidity in pediatrics. The Pediatric Respiratory Disease Therapeutics Market is segmented by Drug Class (Anti-Inflammatory Drugs, Bronchodilators, Combination Drugs, Corticosteroids, Monoclonal Antibodies, and Others), Disease (Asthma, Cystic Fibrosis, Bronchiolitis, Pneumonia, Tuberculosis, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (in USD million) for the above segments.
| Anti-Inflammatory Drugs |
| Bronchodilators |
| Combination Drugs |
| Corticosteroid |
| Monoclonal Antibodies |
| Other Drug Classes |
| Asthma |
| Cystic Fibrosis |
| Bronchiolitis |
| Pneumonia |
| Tuberculosis |
| Other Diseases |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
| By Drug Class | Anti-Inflammatory Drugs | |
| Bronchodilators | ||
| Combination Drugs | ||
| Corticosteroid | ||
| Monoclonal Antibodies | ||
| Other Drug Classes | ||
| By Disease | Asthma | |
| Cystic Fibrosis | ||
| Bronchiolitis | ||
| Pneumonia | ||
| Tuberculosis | ||
| Other Diseases | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Asia-Pacific | China | |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Middle East and Africa | GCC | |
| South Africa | ||
| Rest of Middle East and Africa | ||
| South America | Brazil | |
| Argentina | ||
| Rest of South America | ||
Key Questions Answered in the Report
What is the current Pediatric Respiratory Disease Therapeutics Market size?
The Pediatric Respiratory Disease Therapeutics Market is projected to register a CAGR of 5.6% during the forecast period (2025-2030)
Who are the key players in Pediatric Respiratory Disease Therapeutics Market?
Regeneron Pharmaceuticals, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, F. Hoffmann-La Roche AG and Novartis AG are the major companies operating in the Pediatric Respiratory Disease Therapeutics Market.
Which is the fastest growing region in Pediatric Respiratory Disease Therapeutics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Pediatric Respiratory Disease Therapeutics Market?
In 2025, the North America accounts for the largest market share in Pediatric Respiratory Disease Therapeutics Market.
What years does this Pediatric Respiratory Disease Therapeutics Market cover?
The report covers the Pediatric Respiratory Disease Therapeutics Market historical market size for years: 2021, 2022, 2023 and 2024. The report also forecasts the Pediatric Respiratory Disease Therapeutics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Page last updated on:
Pediatric Respiratory Disease Therapeutics Market Report
Statistics for the 2025 Pediatric Respiratory Disease Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Pediatric Respiratory Disease Therapeutics analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
